



HAL
open science

The CDK4-pRB-E2F1 pathway controls insulin secretion.

Jean-Sébastien Annicotte, Emilie Blanchet, Carine Chavey, Irena Iankova, Safia Costes, Said Assou, Jacques Teyssier, Stéphane Dalle, Claude Sardet, Lluís Fajas

► To cite this version:

Jean-Sébastien Annicotte, Emilie Blanchet, Carine Chavey, Irena Iankova, Safia Costes, et al.. The CDK4-pRB-E2F1 pathway controls insulin secretion.. *Nature Cell Biology*, 2009, 11 (8), pp.1017-23. 10.1038/ncb1915 . inserm-00418907

HAL Id: inserm-00418907

<https://inserm.hal.science/inserm-00418907>

Submitted on 15 Jan 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The CDK4-pRB-E2F1 pathway controls insulin secretion

Jean-Sébastien Annicotte^{1, 2, 7}, Emilie Blanchet^{1, 2, 7}, Carine Chavey^{1, 2}, Irena Iankova^{1, 2}, Safia Costes³, Said Assou⁴, Jacques Teyssier^{1, 2}, Stéphane Dalle³, Claude Sardet⁵, and Lluis Fajas^{1, 2, 6}

¹ INSERM, U834, Montpellier, F-34298, France ; ² IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France ; INSERM, U896, Montpellier, F-34298, France ; Univ Montpellier1, Montpellier, F-34298, France ; CRLC Val d'Aurelle Paul Lamarque, Montpellier, F-34298, France ; ³ CNRS, UMR5203, Institut de Génomique Fonctionnelle, Montpellier, F-34094, France ; INSERM, U661, Equipe AVENIR, Montpellier, F-34094, France ; Univ Montpellier1, 2, Montpellier, F-34094, France; ⁴ Centre Hospitalier Universitaire, Institute for Research in Biotherapy, Hôpital Saint Eloi, Montpellier, F-34295, France ; ⁵ Institut de Génétique Moléculaire, Montpellier, F-34293, France ; CNRS, UMR5535, Montpellier, F-34293, France ; Univ Montpellier2, Montpellier, F-34293, France ; ⁶ Centre Hospitalier Universitaire Arnaud de Villeneuve, Montpellier, F-34295, France

Correspondence should be addressed to : L. F. ¹ e-mail : lluis.fajas@inserm.fr

⁷ These authors contributed equally to this work

Running title : E2F1 and insulin secretion

Abstract

CDK4-pRB-E2F1 cell cycle regulators are robustly expressed in non-proliferating β -cells, suggesting that besides the control of β -cell number the CDK4-pRB-E2F1 pathway has a role in β -cell function. We show here that E2F1 directly regulates the expression of *Kir6.2*, which is a key component of the K_{ATP} channel involved in the regulation of glucose-induced insulin secretion. We demonstrate, by *in tissue* chromatin immunoprecipitation analysis that *Kir6.2* expression is regulated at the promoter level by the CDK4-pRB-E2F1 pathway. Consistently, inhibition of CDK4, or genetic inactivation of E2F1 results in decreased expression of *Kir6.2*, impaired insulin secretion, and glucose intolerance in mice. Furthermore we show that rescue of *Kir6.2* expression restores insulin secretion in *E2f1* $-/-$ β -cells. Finally, we demonstrate that CDK4 is activated by glucose through the insulin pathway, ultimately resulting in E2F1 activation and consequently in *Kir6.2* increased expression. In summary we provide evidence that the CDK4-pRB-E2F1 regulatory pathway is involved in glucose homeostasis, defining a new link between cell proliferation and metabolism.

E2F transcription factors exist either as free E2F/DP heterodimers, or associated in larger complexes containing members of the retinoblastoma (pRB, p107, p130), and of the cyclin/cdk protein families. Association of E2Fs with the pRB family facilitates active repression through recruitment of histone deacetylases¹ and lysine/arginine methyltransferases². Subsequent phosphorylation of the retinoblastoma protein by the cyc/cdk complexes results in the release of the E2F transcription factors and activation of the transcription of genes required for progression through G1 into the S phase of the cell cycle. It is now accepted that E2Fs participate in cellular processes beyond the cell cycle, including apoptosis, differentiation, and development (reviewed in³). Of particular interest is the observation that E2Fs could be involved in the regulation of a metabolic network, including the control of mitochondrial function⁴. We recently implicated E2Fs in the control of adipocyte differentiation⁵. Furthermore, we also showed an overall reduction in pancreatic size, as the result of impaired postnatal pancreatic growth in *E2f1*^{-/-} mice⁶. Surprisingly, we observed that E2F1 was highly expressed in non-proliferating pancreatic β -cells⁶, suggesting that besides its impact on β -cell number, E2F1 could also play a role in pancreatic β -cell function and insulin secretion. Pancreatic β -cell K_{ATP} channels are composed by the heteromeric association of the sulfonylurea receptor 1 (SUR1) with the K^+ ATP channel inward rectifier (KIR6.2). These channels play a critical role in the regulation of glucose-induced insulin secretion by controlling membrane polarization^{7,8}.

The first result suggesting a role of the CDK4-pRB-E2F1 pathway in pancreas physiology, independent of cell proliferation was the observation that E2F1, cyclin-dependent kinase-4 (CDK4) and pRB were expressed in almost all insulin-producing β -cells (Fig. 1a), whereas only a few of these cells (6%) were proliferating, as assessed by PCNA labeling (Fig. 1b, and Fig. S1b). Co-immunoprecipitation assays further indicated coexpression of pRB and E2F1 in these cells (Fig. S1a). Participation of CDK4-pRB-E2F1 in glucose homeostasis was revealed by intra-peritoneal glucose tolerance test (IPGTT) showing that *E2f1*^{-/-} mice are glucose intolerant (Fig. 1c, and⁶). Interestingly, insulin secretion in response to glucose was

impaired in both *E2f1*^{-/-} mice (Fig. 1d), and *E2f1*^{-/-} isolated islets (Fig. 1e). No differences in insulin content were observed in *E2f1*^{-/-} and +/+ cells, when normalized by DNA content (Fig. S1c). This suggested that E2F1 is critical to maintain normal blood glucose levels through the control of insulin secretion in a cell autonomous manner, rather than defects in insulin synthesis. The lack of sensitivity of *E2f1*^{-/-}, compared to +/+ mice to glibenclamide, which is an antidiabetic drug of the sulfonylurea family that stimulates insulin secretion, and therefore decreases glycemia by blocking ATP-sensitive potassium channel in pancreatic β -cells suggested that E2F1 is involved in insulin secretion through the controls of mechanisms such as plasma membrane depolarization (Fig. 1f).

We next identified E2F1 target genes that could mediate the effects of E2F1 in β -cell biology. Comparative gene expression profiling revealed that several genes known to be involved in insulin production or secretion were differentially expressed between *E2f1*^{-/-} and *E2f1*^{+/+} pancreatic islets (Fig. S2a, and supplementary table 1 and 2). Notably, mRNA expression of *Kir6.2* (also referred as *Kcnj11*), which is subunit of the inwardly rectifying and ATP-sensitive potassium channel was strongly decreased in *E2f1*^{-/-} compared to +/+ islets, whereas expression of other genes involved in the control of insulin secretion, such as the sulfonylurea receptor *Sur1*, the pyruvate carboxylase (*Pcx*) or the uncoupling protein 2 (*Ucp2*), were not significantly changed (Fig. 2a). Consistent with this observation knock-down of E2F1 by siRNA decreased endogenous *Kir6.2* mRNA in isolated islets and in Min6 cells (Fig. 2c-d, and Fig. S2c), which followed the expected decrease in E2F1 protein (Fig. 2d). This resulted in decreased glucose-stimulated insulin secretion in Min6 cells (Fig. S2d). Most importantly, rescue of *Kir6.2* expression in *E2f1*^{-/-} isolated islets restored glucose-stimulated insulin secretion in these cells, demonstrating that *Kir6.2* mediated the observed effects of E2F1 in insulin secretion (Fig. 2e, and Fig. S2e).

Computational analysis of the murine *Kir6.2* promoter sequence revealed the presence of an E2F binding site located 577 base pairs upstream of the transcription start site (Fig. S3a). Transient transfection experiments indicated that the E2F1/DP-1 heterodimer could activate the *Kir6.2* promoter up to 10-fold induction (Fig. 2f). This transactivation capability was abrogated when the E2F1 response element found in the *Kir6.2* promoter was mutated,

suggesting that E2F1 was directly involved in the control of *Kir6.2* promoter activity (Fig. 2f). Binding of E2F1 on the promoter region of the *Kir6.2* gene was demonstrated by chromatin immunoprecipitation (ChIP) experiments on genomic DNA isolated from whole pancreatic tissues. A fragment of the mouse *Kir6.2* promoter containing the E2F binding site was amplified by PCR when different anti-E2F1 antibodies were used (Fig. 2g and Fig. S3b). Same results were observed when chromatin isolated from islets was used (Fig. 2h). No E2F1 was detected in a non-related genomic region, or in extracts from *E2f1*^{-/-} pancreas, demonstrating the specificity of the binding (Fig. 2g, and Fig. S3c). Direct binding of E2F1 to this site, at the same extent that to the consensus E2F1 binding site was shown by EMSA (Fig. S3d). Furthermore, E2F1 could not bind to a mutated version of the E2F site in the *Kir6.2* promoter in the same assay (Fig. S3d). These results demonstrated that E2F1 regulates *Kir6.2* expression through direct promoter binding in a cell-autonomous manner. Same results were obtained when Min6 cells were used (Fig. S3e). In this cellular context, E2F1 was equally well associated to the *Kir6.2* or *Dhfr* promoter, suggesting that the E2F1 response element found in the *Kir6.2* promoter could be considered as a *bona fide* E2F1 target gene (Fig. S3e).

E2F1 transcriptional activity is regulated through interactions with pocket proteins and cdks. When associated to pRB, E2Fs repress transcription. Upon phosphorylation of pRB by cdks, E2F1 is released and activates transcription of its target genes (reviewed in⁹). Since E2F1 can regulate the expression of *Kir6.2* (Fig. 2), and *Kir6.2* mRNA expression is regulated by glucose (Fig. 3a, and ¹⁰) we hypothesized that a glucose load could trigger the E2F1 pathway through inactivation of pRB by phosphorylation in pancreatic β -cells. This was demonstrated by the observed increase of pancreatic CDK4 activity in response to glucose in mice, as measured by the capacity of immunoprecipitated CDK4 to phosphorylate recombinant pRB protein *in vitro* (Fig. 3b). Consistent with this increase in CDK4 activity, enhanced pRB phosphorylation was observed in pancreatic islets in response to intra-peritoneal glucose injection (Fig. 3c and Fig. S4). We also showed that glucose-induced phosphorylation of pRB increased E2F1 transcriptional activity in *Kir6.2* promoter-reporter assays. Glucose treatment increased *Kir6.2* promoter activity in the presence of the E2F1/DP-

1 heterodimer, whereas no induction was observed when the E2F1 responsive element in the *Kir6.2* promoter construct was mutated (Fig. 3d). Moreover, co-transfection of increasing amounts of pRB counteracted the stimulatory effects of E2F1 on the *Kir6.2* promoter (Fig. 3e). Similarly, cell treatment with the CDK4 inhibitor, 2-Bromo-12,13-dihydro-5H-indolo(2,3-a)pyrrolo (3,4)carbazole (IDCX), also repressed this E2F1-mediated transactivation of the *Kir6.2* promoter activity (Fig. 3e). These results were further validated by *in vivo* ChIP experiments. E2F1 was associated to the *Kir6.2* promoter regardless of glucose treatment (Fig. 3f). In sharp contrast, pRB was only associated to this promoter region in the absence of glucose treatment, suggesting that glucose facilitated pRB release from the E2F1 complex bound to the *Kir6.2* promoter (Fig. 3f). This is consistent with the known repressor effect of hypophosphorylated pRB on E2F1 activity. To further prove that E2F1 and pRB are part of the same complex re-ChIP experiments were performed. After a first ChIP using anti-E2F1 antibody, a second immunoprecipitation using an anti-pRB antibody or non-specific IgGs was performed. Same results as in simple ChIP experiments were observed, demonstrating that pRB forms a complex with E2F1 in this promoter under these conditions (Fig. 3g). Finally, the physiological relevance of pRB phosphorylation was evaluated during glucose-stimulated insulin secretion. Transient transfection of a pRB non-phosphorylatable mutant (pRB- Δ p34,¹¹) in Min6 cells resulted in a hypophosphorylated form of pRB upon normal and glucose-stimulated conditions, whereas the wild-type form was still sensitive to phosphorylation (Fig. 3h). Most importantly, expression of this mutant in Min6 cells resulted in decreased *Kir6.2* mRNA expression (Fig. 3i) and subsequent glucose-stimulated insulin secretion (Fig. 3j). We can conclude from these results that phosphorylation of pRb is involved in glucose-stimulated insulin secretion through the transcriptional control of *Kir6.2* mRNA expression. Taken together these results suggested that glucose increases CDK4 activity, alleviates pRB-mediated repression and activates E2F1 transcriptional activity towards *Kir6.2*, highlighting a novel role for the CDK4-pRB-E2F1 pathway in the control of the insulin/glucose metabolic response in pancreatic islets.

In pancreatic β -cells, insulin regulates expression of genes such as *insulin* gene itself¹², or *glucokinase*¹³ in response to glucose through autocrine effects. We therefore wanted to

evaluate whether CDK4-pRB-E2F1 regulation of *Kir6.2* expression by glucose was direct or rather mediated by insulin autocrine effects. Concomitant treatment of glucose and diazoxide, which is a synthetic inhibitor of insulin secretion in β -cells through opening of K^+ channels abrogated the positive effect of glucose on *Kir6.2* mRNA expression in these cells (Fig. 4a). This transcriptional effect was mediated by E2F1 as evidenced by the absence of effect in *E2f1* $-/-$ islets (Fig. 4a). Increased *Kir6.2* expression in response to glucose correlated with increased CDK4 activity in pancreas of glucose-treated mice, as demonstrated by CDK4 kinase assays following immunoprecipitation of equal amounts of CDK4 (Fig. 4b). Interestingly, blockade of insulin secretion with diazoxide, or inhibition of insulin signaling with LY290034, which is a PI3K inhibitor resulted in the abrogation of CDK4 activity in these mice (Fig. 4b). The resulting decrease in CDK4 activity upon diazoxide treatment was correlated to increased binding of the repressor pRB-E2F1 complex on the *Kir6.2* promoter, as demonstrated by *in vivo* ChIP and Re-ChIP experiments (Fig. 4c-d). This was consistent with the observed decrease in *Kir6.2* mRNA expression. Similar to diazoxide treatment, mice under fasting conditions show inhibited insulin secretion. Consistently, the pRB-E2F1 repressor complex is associated to the *Kir6.2* promoter. Conversely, glucose or insulin infusion of mice resulted in pRB phosphorylation (Fig. 4c-d) and release from the E2F1 complex on the *Kir6.2* promoter, leading to increased E2F1 transcriptional activity, as indicated by increased histone acetylation in this promoter region (Fig. 4c-d). Taken together these results suggested that the effect of glucose on CDK4 activity, pRB phosphorylation and E2F1 transcriptional activity are mediated through an autocrine effect of insulin on β -cells, secondary to glucose-stimulated insulin secretion.

We next investigated whether increased CDK4 activity upon glucose and insulin treatment could be the result of increased regulatory activity of D-type cyclins, which are major regulators of CDK4. We observed a 2- to 3-fold increase in binding of Cyclin D2 to CDK4 in Min6 cells treated with glucose, and most importantly with insulin, suggesting that insulin and glucose could exert their positive effects on CDK4 activity through an increase in cyclin D2 and CDK4 mRNA levels and subsequent protein-protein interaction (Fig. 4e-f). Cell cycle is tightly regulated, with D-type cyclins acting as growth factors sensors. Upon

mitogenic stimulation, D-type cyclins expression and assembly into CDK complexes is increased, finally resulting in cell cycle progression. Interestingly, we observed that treatment of Min6 cells with growth factors, *i.e.* EGF or IGF, resulted in increased mRNA levels of *CcnD2* and *Cdk4*, and most importantly, increased *Kir6.2* (Fig. 4g-h). Altogether, these data indicate that CDK4 activity is regulated upon growth factor stimuli through increased mRNA levels of *CcnD2* and *CDK4*, resulting in increased association of Cyclin D2 and CDK4, which finally increases mRNA *Kir6.2* expression.

Finally, to unequivocally implicate the CDK4-pRB-E2F1 pathway in the control of glucose homeostasis, we evaluated the effects of pharmacological inhibition of CDK4 activity on glucose tolerance and insulin secretion in mice. Clearance of injected glucose, as evaluated by IPGTT was dramatically decreased in treated, compared to non-treated mice with IDCX, which is a specific CDK4 inhibitor (Fig. 5a). This was consistent with decreased glucose-stimulated insulin secretion in IDCX treated, compared to non-treated mice (Fig. 5b). In addition, inhibition of CDK4 activity *in vivo* resulted in decreased *Kir6.2* mRNA and protein levels (Fig 5c-d). These results are of particular interest since they are closely related to those observed in *E2f1* *-/-* mice and reinforce our hypothesis that the CDK4-pRB-E2F1 pathway plays a crucial role in the control of glucose homeostasis.

We have previously demonstrated the importance of cell cycle regulators, in particular E2Fs in the control of post-natal pancreatic β -cell growth and replication. Decreased proliferation and renewal rate of pancreatic β -cells could not fully explain, however the observed decrease in insulin secretion in *E2f1* *-/-* mice. We provide now enough evidence to propose that cell cycle regulators, in particular the CDK4-pRB-E2F1 pathway are critical mediators of nutrient sensing and insulin secretion. This is supported by several findings. First, E2F1, CDK4, and pRB proteins are highly expressed in β -cells. Only few of these cells are, however proliferating despite high levels of expression of these cell cycle regulators, suggesting an additional role of these proteins in β -cells. Second, we show that E2F1 translates nutritional signaling, such as glucose to a metabolic, and not proliferative response through the transcriptional regulation of specific β -cell genes involved in insulin secretion, such as *Kir6.2*. Consistent with this, we found that *Kir6.2* mRNA and protein were almost

absent in *E2f1* *-/-* pancreatic β -cells, and rescue of *Kir6.2* expression in *E2f1* *-/-* islets restored glucose-stimulated insulin secretion. We show that E2F1-pRB directly bind to the *Kir6.2* promoter, as demonstrated by *in vivo* ChIP assays. Furthermore we show that the cyclin D-CDK4-pRB-E2F1 pathway is involved in the transcriptional activation of the *Kir6.2* promoter. Strikingly, the phenotype of *Kir6.2* *-/-* mice strongly resembles *E2f1* *-/-* mice phenotype. Both show impaired insulin secretion. Furthermore, these mice are not diabetic although impaired glucose-stimulated insulin secretion because of their increased insulin sensitivity in peripheral tissues^{14,6,5,15}. These observations underline a close link between E2F1 and KIR6.2 in metabolic function. Finally, we demonstrate that the CDK4-pRB-E2F1 pathway is regulated through an autocrine effect of insulin on β -cells, secondary to glucose-stimulated insulin secretion. We demonstrate here that upon high glucose concentration, β -cells respond by inducing insulin secretion, which subsequently induces the activation of transcription by an autocrine effect (Fig. S5). Transcriptional activation in β -cells is controlled, at least in part by insulin signaling through the PI3 kinase/AKT pathway. We show that this pathway is implicated on the CDK4-pRB-E2F1-mediated transcriptional regulation, through increasing CDK4 kinase activity. CDK4, on its turn phosphorylates pRB, and releases E2F1-DP complex, which activate transcription of *Kir6.2*. Consistent with our hypothesis is the finding that CDK4 activity was increased in transgenic mice over-expressing a constitutively active form of AKT in β -cells (caAKT^{Tg}; ¹⁶).

Participation of other cell cycle regulators of the CDK4-pRB-E2F1 pathway in the metabolic response of pancreatic β -cells is likely. Similar to *E2f1* *-/-* mice, *cyclin D1* *-/-*, and *cyclin D2* *-/-* mice show decreased β -cell mass, concomitantly with decreased insulin levels^{17,18}. Conversely, mice with gene inactivation of the cell cycle inhibitors p27^{19,20} or p16 INK4A²¹ have increased islet mass. These observations raise the question of how this cell cycle regulatory pathway can regulate both cell proliferation and metabolism in β -cells. In line with this duality is the established role of insulin as an important factor for both β -cell proliferation, and β -cell metabolic function²²⁻²⁵. Since our findings indicate that the CDK4-pRB-E2F1 pathway is regulated by insulin, we can hypothesize that both the proliferative and

metabolic effects of insulin on β -cells are mediated by the increase of CDK4 activity and subsequent E2F1 transcriptional activity (Fig. 4).

In summary, we have shown that the CDK4-pRB-E2F1 pathway mediates the transcriptional response to glucose of genes implicated in insulin secretion, such as Kir6.2. These results underscore a dual role of the E2F1 pathway in the control of both cell proliferation, and metabolic response.

Acknowledgments

We thank Dr K.H. Kaestner (pGL3-Kir6.2-Luc), Pr S. Seino and Pr Y. Kurachi (pCDNA3-Kir6.2) for the gift of materials, I. Ait Arssa, M. Brissac, C. Clapé, D. Greuet, C. Henriquet and S. Hure for excellent technical help. Dr L. Le Cam, and members of the Fajas' lab are acknowledged for support and discussions. This work was supported by grants from Agence Nationale pour la Recherche (ANR physio2006), INSERM-Association Française des Diabétiques (PNR-Diabète), Association pour la Recherche contre le Cancer, and Fondation pour la Recherche Médicale. E.B. is supported by a grant from the Ministère de l'Enseignement Supérieur et de la Recherche, C.C. is supported by a grant from the Agence Nationale pour la Recherche.

Author contributions

J-S. A. and L.F designed the study. J-S. A., E.B., C.C., I.I., S.C., S.A. and J.T performed the experiments. S.D. and C.S. provided reagents and data. J-S. A. and L.F wrote the manuscript.

Figure legends

Figure 1. Decreased secretagogue-stimulated insulin secretion in *E2f1* $-/-$ mice.

a, Immunofluorescence analysis of serial pancreatic sections showing co-expression of E2F1, CDK4 and pRB (green) in β -cells, as demonstrated by insulin staining (red). Nuclei are stained with Hoechst reagent. Scale bars represent 100 μ m.

b, The Proliferating Cell Nuclear Antigen (PCNA, black arrow) proliferation marker is detected in β -cells (insulin, pink) by immunohistochemistry. Cells were counterstained with methyl green. Scale bars represent 100 μ m.

c, d, IPGTT measuring the levels of glucose (c) and insulin (b) at the indicated times after an intra-peritoneal injection of glucose in *E2f1* *+/+* and *-/-* mice (means \pm s.e.m., n=7).

e, Insulin secretion of *E2f1* *+/+* and *-/-* isolated islets in the presence of 2.8 mM and 20 mM glucose. Results were normalized by total insulin content. A representative result of 5 independent experiments is shown (means \pm s.e.m.).

f, Serum glucose levels were determined before and 60 minutes after intra-peritoneal injection of glibenclamide (means \pm s.e.m., n=5).

Figure 2. *Kir6.2*, a component of the K_{ATP} channels regulating insulin secretion, is a direct E2F1 target gene.

a, Gene expression analysis in *E2f1* *+/+* and *-/-* isolated islets. Quantification of the expression by Q-PCR of *E2f1* and relevant genes involved in insulin secretion. *Kir6.2*, inwardly rectifying potassium channel ; *Sur1*, sulfonyl urea receptor 1 ; *Pcx*, pyruvate carboxylase ; *Ucp2*, uncoupling protein-2 (means \pm s.e.m., n=5).

b, Western blot showing KIR6.2 expression in *E2f1* *+/+* and *-/-* pancreas.

c, Quantification of *E2f1* and *Kir6.2* mRNA expression in *E2f1* *+/+* isolated islets transfected with siRNA-control or siRNA-E2F1. The experiment was performed in triplicate (means \pm s.e.m., n=3).

d, Western blot showing E2F1 expression in isolated islets transiently transfected with a siRNA control or a siRNA targeting *E2f1* mRNA. Actin was used as a loading control.

e, Insulin secretion of *E2f1* *+/+* and *-/-* isolated islets transfected with pCDNA3 or pCDNA3-m*Kir6.2* in the presence of 2.8 mM and 20 mM glucose. Results were normalized by total insulin and DNA content (means \pm s.e.m., n=3).

f, The E2F1/DP-1 heterodimer modulates *Kir6.2* promoter activity. COS7 cells were transiently co-transfected with the pGL3 (empty vector, negative control), the *Kir6.2* promoter (*Kir6.2*-luc) and the mutated E2F1 responsive element *Kir6.2* promoter (*mutKir6.2*-

luc) luciferase constructs in the presence or absence of E2F1/DP-1. Results were normalized to β -galactosidase activity and are expressed as relative luciferase units (R.L.U.).

g, ChIP demonstrating specific binding of E2F1 to the *Kir6.2* promoter. Cross-linked chromatin from *E2f1* *+/+* and *-/-* pancreata were incubated with two different antibodies against E2F1 or IgG. Immunoprecipitates were analyzed by PCR using specific primers for the E2F-RE present in the *Kir6.2* promoter. As a control, a sample representing 10% of the total chromatin was included in the PCR (Input).

h, ChIP demonstrating specific binding of E2F1 to the *Kir6.2* promoter in isolated islets. Cross-linked chromatin from *E2f1* *+/+* and *-/-* isolated islets were incubated with antibodies against E2F1 or IgG. Immunoprecipitates were analyzed as in **g**. See Supplementary Information, Fig S6 for full scans of blots in **b** and **d**.

Figure 3. Glucose regulates CDK4 activity, pRB phosphorylation and E2F1 transcriptional activity both *in vitro* and *in vivo*.

a, *Kir6.2* mRNA levels following glucose treatment of isolated islets (means \pm s.e.m, n=3).

b, CDK4 activity *in vivo*. SDS-PAGE autoradiography showing phosphorylated purified pRB by immunoprecipitated CDK4 from pancreata after an intra-peritoneal injection of glucose (lane 2) or a saline solution (lane 1). As a positive control for pRb phosphorylation, purified CyclinD3/CDK4 proteins were used (lane 3).

c, Quantification of phosphorylated pRB in pancreatic islets after *in vivo* injection of glucose. Mice were treated with (n=5) or without glucose (n=5), killed one hour post-injection. Pancreata were then collected, fixed in 4% PFA and subsequently processed for paraffin embedding. IHC was performed on pancreas sections using an anti-phospho pRb antibody. Total and positively-stained cells were counted. Around 50 islets per condition were counted (means \pm s.e.m., n=5).

d, Glucose treatment modulates the *Kir6.2* promoter activity in the presence of E2F1/DP-1 heterodimer. Min6 cells were treated as indicated, and results are presented in fold induction.

e, Activity generated by the *Kir6.2*-Luc reporter cotransfected with the E2F1/DP-1 expression vector in the absence or presence of increasing amount of wild-type pRB and the CDK4

inhibitor IDCX (1, 5 and 10 μ M). Experiments were performed in COS7 cells in the presence of glucose.

f, CHIP demonstrating binding of E2F1 and pRB to the *Kir6.2* promoter. As a control, a sample representing 10% of the total chromatin was included in the PCR (Input).

g, Re-ChIP assays demonstrating interaction between E2F1 and pRB on the *Kir6.2* promoter. Immunoprecipitates were analyzed as in **f**.

h, Western blot analysis of pRb phosphorylation status in Min6 cells upon glucose treatment transiently transfected with wild-type pRb or a phosphorylation-defective constitutive active pRB mutant construct (pRB Δ p34).

i, Quantification of *Kir6.2* mRNA expression in Min6 cells transfected with wild-type pRb (pRb wt) or pRB Δ p34 treated or not with 20mM glucose (means \pm s.e.m., n=3).

j, Insulin secretion of Min6 cells transfected with pRb wt or pRB Δ p34 in the presence of 2.8 mM and 20 mM glucose. Results are presented as fold induction compared to 2.8 mM glucose (means \pm s.e.m, n=3). See Supplementary Information, Fig S6 for full scans of blots in **b** and **h**.

Figure 4. Insulin regulates CDK4 activity, pRB phosphorylation and E2F1 transcriptional activity *in vivo* through an autocrine effect.

a, *Kir6.2* mRNA levels in *E2f1* *+/+* and *-/-* isolated islets 1 hour after glucose, insulin, diazoxide and glucose/diazoxide treatment. The experiment was done using \sim 20 islets per condition in triplicate (means \pm s.e.m.).

b, CDK4 activity in *E2f1* *+/+* pancreata. SDS-PAGE autoradiography showing radiolabelled phosphorylated purified pRB (33 P pRb) by immunoprecipitated CDK4 from pancreatic tissue of mice treated 1 hour as indicated (lane 1 to 4). As a positive control for pRb phosphorylation, purified Cyclin D3/CDK6 proteins were used (lane 5).

c, CHIP showing differential binding of E2F1 and pRb to the *Kir6.2* promoter in the pancreas of mice treated as indicated.

d, Re-ChIP assays demonstrating differential interaction between E2F1 and pRB on the *Kir6.2* promoter. Chromatin was prepared from pancreatic tissues obtained after i.p. injection

of a saline, a glucose, an insulin or glucose/diazoxide solution and subjected to the ChIP procedure with the antibody against E2F1 and re-immunoprecipitated using IgG or anti-pRB antibody. Immunoprecipitates were analyzed as described above.

e, Representative immunoprecipitation (IP) assays showing interaction between CCND2 and CDK4. Immunoblot (IB) analysis revealed an increased interaction between CDK4 and CCND2 in Min6 cells after glucose and insulin treatment.

f, Densitometry analysis of results shown in 4e, and in two independent experiments. Results are expressed as the ratio of the signal reported to the input signal (means \pm s.e.m.). Images were analyzed by ImageJ software.

g, Quantification of *Cyclin D2* (*CcnD2*) and *Cdk4* mRNA levels in Min6 cells treated or not with 5 nM EGF or 10 nM IGF (triplicate, means \pm s.e.m.).

h, *Kir6.2* mRNA levels in Min6 cells treated as described (triplicate, means \pm s.e.m.). See Supplementary Information, Fig S6 for full scans of blots in **b** and **e**.

Figure 5. Glucose intolerance, decreased insulin secretion and KIR6.2 levels in C57Bl/6 treated with CDK4 inhibitor.

a, b, IPGTT measuring the levels of glucose (a) and insulin (b) at the indicated times after an intra-peritoneal injection of glucose in C57/B16J mice treated for 3 days with vehicle or IDCX solutions (means \pm s.e.m., n=4).

c, *Kir6.2*, *Sur1* and *Pcx* mRNA levels in *E2f1* *+/+* islets isolated from mice treated with IDCX as described in **a**. The experiment was done using ~40 islets per condition in triplicate (means \pm s.e.m.).

d, Western blot analysis of KIR6.2 protein levels in *E2f1* *+/+* pancreas isolated from mice treated without (control, n=4) or with IDCX (n=4) as described in **a**. A representative radiography of pancreas from 2 non-treated and treated animals is shown. Levels of induction (n-fold) are indicated. Tubulin was used as a loading control. See Supplementary Information, Fig S6 for full scans of blots in **d**.

Methods

Materials and oligonucleotides. All chemicals, except if stated otherwise, were purchased from Sigma (St Louis, MO, USA). LY290034 and IDCX were purchased from VWR-Calbiochem (Fontenay sous Bois, France). Anti-CDK4 (C-22), anti-E2F1 (C-20 for immunofluorescence, KH-95X for ChIP), anti-KIR6.2 (D-14) and anti-PCNA (PC-10) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-acetyl H4 (Lys 12), anti-pRb and anti-Phospho-Rb (ser 807/811) were from Cell Signaling (Beverly, MA, USA), anti-insulin was from Linco Research (Millipore, Billerica, MA, USA), anti-BrdU was from Dako (Glostrup, Denmark). The oligonucleotide sequences used for various experiments in this manuscript are available upon request.

Protein extracts, co-immunoprecipitation assays and immunoblot analysis. Protein extracts and sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), electrotransfer and immunoblotting were performed as described ²⁶. Co-immunoprecipitation assays were performed as described ²⁷.

Immunofluorescence (IF) and immunohistochemistry (IHC). IF and IHC were performed as described previously ^{6,27}. Briefly, after antigen retrieval, 5 μ m formalin-fixed pancreatic sections were incubated with the indicated antibodies. Immunostainings were revealed using peroxidase-conjugated anti-rabbit (Jackson Immunoresearch, Cambridgeshire, UK) secondary antibodies and the DAB (for PCNA and Phospho-Rb, DAKO, Glostrup, Denmark) and NovaRed (for insulin, Vector Laboratories, Burlingame, USA) chromogens as a substrate. Sections were counterstained with haematoxylin or methyl green. Immunofluorescence stainings were revealed using a FITC-conjugated anti-rabbit (Jackson Immunoresearch), alexa-conjugated anti guinea pig, or anti-goat (for KIR6.2 staining, Jackson Immunoresearch) secondary antibody. Negative controls using rabbit or goat IgGs were performed and no staining was observed in these conditions.

Animal experiments. C57Bl/6J and *E2f1* ^{+/+} and ^{-/-} mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and were maintained according to European Union

guidelines for use of laboratory animals. *In vivo* experiments were performed in compliance with the French guidelines for experimental animal studies (animal house agreement # B-34-172-27, authorization for animal experimentation # 34.324). Glucose and insulin measurements were performed as described ⁶ on overnight-fasted mice immediately before and at the indicated time after intra-peritoneal injections of (dose/body weight) glucose (2g/Kg) and glibenclamide (5mg/Kg). IDCX was intra-peritoneally injected at a dose of 5mg/Kg/day for 3 days.

Pancreatic islet studies. Briefly, small pieces of pancreas were digested by collagenase (1.5 mg/ml) and isolated in oxygenated-Krebs Ringer Bicarbonate Hepes buffer (KRBH) containing 0.5% FFA-free BSA. For insulin secretion assays, approximately five islets per condition were handpicked and exposed to either 2.8 or 20 mM glucose. Insulin released in the medium was measured 1 h later by RIA (Linco Research, Inc., St Charles, USA). For *Kir6.2* re-expression experiments, *E2f1* ^{-/-} islets were isolated as described above and cultured in DMEM medium supplemented with FBS and antibiotics in 12-well plates. Sixteen hours later, isolated islets were transfected with empty pCDNA3 or pCDNA3 encoding the *mKir6.2* cDNA (a kind gift of Pr Y. Kurachi, Osaka University, Japan) using jetPEI (Polyplus Transfection, Illkirch, France) following manufacturer's instructions. Five hours after transfection, medium was replaced by fresh DMEM medium supplemented with FBS and antibiotics and islets were subsequently cultured for 20 h. For siRNA experiments, islets were transfected with DharmaFect2 (2 μ l/ml) and smart-pool E2F1 validated siRNA (100nM) following manufacturer's instructions (Dharmacon, Inc., Lafayette, USA) and cultured for 24 h in DMEM containing 2.8mM glucose and 10% FBS. Islets were then rinsed in PBS, handpicked (approximately five islets per condition, in triplicate) and pre-incubated in oxygenated-KRBH containing 0.5% FFA-free BSA for 30 minutes. After this pre-incubation step, islets transiently transfected with empty pCDNA3, pCDNA3-*mKir6.2*, siRNA-control or siRNA-E2F1 were subsequently incubated in oxygenated-KRBH containing 2.8 or 20 mM glucose. Insulin released in the medium was measured using an insulin ELISA kit (Mercodia, Uppsala, Sweden). Data are expressed as a ratio per DNA or total insulin content. For mRNA quantification, islets were isolated and incubated in KRBH containing 10 mM glucose for 1 h

30, subsequently handpicked and finally incubated with or without 20 mM glucose, 100 nM insulin and/or inhibitors (200 μ M diazoxide) for 1 h. Islets were then processed for mRNA extraction.

RNA extraction, Affymetrix arrays, RT-PCR and Q-PCR. After isolation of *E2f1* $+/+$ and $-/-$ islets RNA extraction and reverse transcription were performed as described ^{6,28}. mRNA expression was measured by quantitative real-time PCR (Q-PCR) with Power SYBR Green master mix using a 7300 ABI PRISM Sequence Detector System (Applied Biosystems, Foster City, USA) according the manufacturer's recommendations. Q-PCR was performed using gene-specific oligonucleotides under the following conditions: 2 minutes at 50°C and 10 minutes at 95°C and then 40 cycle of 15 seconds at 95°C and 1 minute at 60°C. The results were normalized to endogenous 18S reference mRNA expression levels. Values are expressed as the relative mRNA level of specific gene expression as obtained using the formula $2^{-\Delta Ct}$. The oligonucleotide sequences used for various experiments in this manuscript are available upon request. All Affymetrix experiments were performed on the High Density Microarray core facility at the Institute for Research in Biotherapy of the University Hospital of Montpellier (<https://195.220.112.5/http/0/irb.montp.inserm.fr/>).

Site-directed mutagenesis. The pGL3-*Kir6.2*-Luc (a kind gift of Dr K.H. Kaestner, University of Pennsylvania, USA) containing a mutated E2F responsive element (GCCGCCgGcGGgcgccgcTCGGCTCCTGA) was created using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, USA).

Cell culture, transient transfections. The Min6 and COS7 cell lines were derived from stocks routinely maintained in the laboratory. Experiments on Min6 cells were performed between passages 20 to 28. Monolayer cell cultures were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 25 mM glucose and 10% foetal calf serum (FCS) (Invitrogen) for COS7 cells and 15% FCS and 100 mM β -mercaptoethanol for Min6 cells. Transient transfections were performed as described previously ²⁷ using jetPEI (Polyplus Transfection) and pGL3-*Kir6.2*-Luc, pGL3-*mutKir6.2*-Luc pCMV-E2F1 ⁵, pCMV-DP-1 ⁵ pECE-pRbwt and pECE-pRb Δ p34 ¹¹. Luciferase activity measurements were normalized for β -galactosidase activity to correct for differences in transfection efficiency. Graph values

represent the mean of three independent experiments. For glucose treatment experiments, cells were maintained in glucose free DMEM overnight, transfected and treated 8 h after transfection when stated with glucose for 24 h. Cells were then harvested and luciferase activity was measured.

Chromatin immunoprecipitation (ChIP) and Re-ChIP. ChIP and Re-ChIP assays were performed as described previously ²⁷. Briefly, proteins from Min6 cells or pancreatic tissues were formaldehyde cross-linked to DNA. After homogenization, lysis and DNA sonication, proteins were then immunoprecipitated using purified IgGs, anti-E2F1, anti-pRb or anti-acetyl H4 antibodies. After washing, for Re-ChIP experiment, DNA-protein-complexes were incubated in 10mM dithiothreitol (DTT) at 37°C for 30 min, diluted in Re-ChIP buffer and subjected to a second immunoprecipitation. After washing, DNA-protein-complexes obtained from ChIP and Re-ChIP experiment were subsequently eluted and cross-linking was reversed by heating the samples at 65°C for 16 h. DNA was then purified using Qiagen PCR purification kit (Qiagen, Courtabœuf, France) and PCR amplification was performed using *Kir6.2*, *FABP4*, and *Dhfr* promoter-specific primers.

EMSA. Electromobility shift assays were performed exactly as previously described using nuclear extracts from transfected Min6 cells with E2F1 and DP1 expression vectors ²⁷ and radiolabelled gene-specific oligonucleotides (E2F-Dhfr, 5'-AATTCTGCGATTTTCGCGCCAAACTTGACG-3'; E2F-Kir, 5'-TCAGGAGCCGATCTGGCGCCCTCTGGCGGC-3'; E2F-mutKir, 5'-TCAGGAGCCGAGCGGCCCGCCCGCGGC-3').

Kinase assays. Mice were fasted 16 hours, intra-peritoneally injected with glucose (2 g/Kg) and glucose (2 g/Kg) combined with diazoxide (25 mg/Kg) or LY290034 (100 mg/Kg). Mice were then sacrificed and CDK4 immunoprecipitation and kinase assays were performed exactly as previously described ²⁹. Briefly, kinase assays were performed using immunoprecipitated CDK4 and 100 ng of recombinant Rb protein (Santa Cruz, California) as a substrate. Reactions were performed in kinase buffer (25mM Tris/HCl [pH 7.5], 150 mM NaCl, 10 mM MgCl₂, 1mM DTT, 5 mM Na₄P₂O₇, 50 mM NaF, 1 mM vanadate and protease inhibitor cocktail (Sigma, St. Louis, Missouri)) using 40 μM ATP and 8 μCi [γ-³³P]

ATP for 30 min at 37°C. CDK6/cycD3 kinase (Upstate, Charlottesville, Virginia) was used as positive control. The reaction was stopped by boiling the samples for 5 min in the presence of denaturing sample buffer. Samples were subsequently subjected to SDS-PAGE, and the gels were then dried in a gel dryer for 1 hr at 80°C and exposed to an X-ray film.

Statistical analysis. Data are presented as means \pm s.e.m. Statistical analysis were performed with unpaired Student's t-test. Differences were considered statistically significant at $p < 0.05$. (* $p < 0.05$; ** $p < 0.01$ and *** $p < 0.001$).

References

1. Brehm, A. et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. *Nature* 391, 597-601. (1998).
2. Fabbriozio, E. et al. Negative regulation of transcription by the type II arginine methyltransferase PRMT5. *EMBO Rep* 3, 641-5 (2002).
3. Dimova, D. K. & Dyson, N. J. The E2F transcriptional network: old acquaintances with new faces. *Oncogene* 24, 2810-26 (2005).
4. Cam, H. et al. A common set of gene regulatory networks links metabolism and growth inhibition. *Mol Cell* 16, 399-411 (2004).
5. Fajas, L. et al. E2Fs regulate adipocyte differentiation. *Dev Cell* 3, 39-49. (2002).
6. Fajas, L. et al. Impaired pancreatic growth, beta cell mass, and beta cell function in E2F1 (-/-) mice. *J Clin Invest* 113, 1288-95 (2004).
7. Miki, T., Nagashima, K. & Seino, S. The structure and function of the ATP-sensitive K⁺ channel in insulin-secreting pancreatic beta-cells. *J Mol Endocrinol* 22, 113-23 (1999).
8. Lorenz, E. et al. Evidence for direct physical association between a K⁺ channel (Kir6.2) and an ATP-binding cassette protein (SUR1) which affects cellular distribution and kinetic behavior of an ATP-sensitive K⁺ channel. *Mol Cell Biol* 18, 1652-9 (1998).
9. Helin, K. Regulation of cell proliferation by the E2F transcription factors. *Curr Opin Genet Dev* 8, 28-35 (1998).
10. Webb, G. C., Akbar, M. S., Zhao, C. & Steiner, D. F. Expression profiling of pancreatic beta cells: glucose regulation of secretory and metabolic pathway genes. *Proc Natl Acad Sci U S A* 97, 5773-8 (2000).
11. Fajas, L. et al. Cyclin A is a mediator of p120E4F-dependent cell cycle arrest in G1. *Mol Cell Biol* 21, 2956-66. (2001).
12. Leibiger, I. B., Leibiger, B., Moede, T. & Berggren, P. O. Exocytosis of insulin promotes insulin gene transcription via the insulin receptor/PI-3 kinase/p70 s6 kinase and CaM kinase pathways. *Mol Cell* 1, 933-8 (1998).
13. Leibiger, B. et al. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic beta cells. *Mol Cell* 7, 559-70 (2001).
14. Remedi, M. S. et al. Diet-induced glucose intolerance in mice with decreased beta-cell ATP-sensitive K⁺ channels. *Diabetes* 53, 3159-67 (2004).

15. Miki, T. et al. ATP-sensitive potassium channels participate in glucose uptake in skeletal muscle and adipose tissue. *Am J Physiol Endocrinol Metab* 283, E1178-84 (2002).
16. Fatrai, S. et al. Akt induces beta-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. *Diabetes* 55, 318-25 (2006).
17. Kushner, J. A. et al. Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. *Mol Cell Biol* 25, 3752-62 (2005).
18. Georgia, S. & Bhushan, A. Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. *J Clin Invest* 114, 963-8 (2004).
19. Rachdi, L. et al. Differential effects of p27 in regulation of beta-cell mass during development, neonatal period, and adult life. *Diabetes* 55, 3520-8 (2006).
20. Uchida, T. et al. Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. *Nat Med* 11, 175-82 (2005).
21. Krishnamurthy, J. et al. p16INK4a induces an age-dependent decline in islet regenerative potential. *Nature* 443, 453-7 (2006).
22. Kulkarni, R. N. et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. *Cell* 96, 329-39 (1999).
23. Otani, K. et al. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. *Am J Physiol Endocrinol Metab* 286, E41-9 (2004).
24. Okada, T. et al. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. *Proc Natl Acad Sci U S A* 104, 8977-82 (2007).
25. Leibiger, I. B., Leibiger, B. & Berggren, P. O. Insulin feedback action on pancreatic beta-cell function. *FEBS Lett* 532, 1-6 (2002).
26. Sarruf, D. A. et al. Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor gamma. *Mol Cell Biol* 25, 9985-95 (2005).
27. Annicotte, J. S. et al. Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. *Mol Cell Biol* 26, 7561-74 (2006).
28. Annicotte, J. S. et al. Pancreatic-duodenal homeobox 1 regulates expression of liver receptor homolog 1 during pancreas development. *Mol Cell Biol* 23, 6713-24 (2003).
29. Abella, A. et al. Cdk4 promotes adipogenesis through PPARgamma activation. *Cell Metab* 2, 239-49 (2005).

Supplementary information

Supplementary tables

Supplementary Information, table I. Genes with decreased expression in pancreas of *E2f1* *-/-* mice.

Supplementary Information, table II. Genes with increased expression in pancreas of *E2f1* *-/-* mice.

Supplementary Information, table III. Oligonucleotide sequences used in this study.

Supplementary figure legends

Figure 3. Glucose regulates CDK4 activity, pRB phosphorylation and E2F1 transcriptional activity both *in vitro* and *in vivo*.

a, The experiment was done using ~20 islets per condition in triplicate.

c, Mice were treated with (n=5) or without glucose (n=5), killed one hour post-injection. Pancreata were then collected, fixed in 4% PFA and subsequently processed for paraffin embedding. IHC was performed on pancreas sections using an anti-phospho pRb antibody.

d, Relative luciferase activity as determined after co-transfection of Min6 cells with the E2F1/DP-1 expression vector and the empty pGL3, the *Kir6.2* or the mutated *Kir6.2* promoter reporter constructs.

e, Experiments were performed in COS7 cells in the presence of glucose.

f, Cross-linked chromatin from pancreatic tissues obtained after i.p. injection of a saline or glucose solution was incubated with antibodies against E2F1, pRB, acetylated H4 or IgG. Chromatin immunoprecipitated with the indicated antibodies was subsequently analyzed by PCR using specific primers for the E2F-RE present in the *Kir6.2* promoter.

g, Chromatin was prepared from pancreatic tissues obtained after i.p. injection of a saline or glucose solution and subjected to the ChIP procedure with the antibody against E2F1 and re-immunoprecipitated using IgG or anti-pRB antibody.

Supplementary figure S1. Interaction of E2F1 with pRB, cell proliferation, and insulin content in islets.

a, Co-immunoprecipitation (IP) assays showing interaction between E2F1 and pRb. 50 pancreatic islets were isolated and immunoprecipitated with IgGs or anti-E2F1. Western blot analysis revealed the presence of pRb and E2F1 in cell lysates before (input, lane 1) and after E2F1 immunoprecipitation (lane 4). No immunoprecipitation of pRb and E2F1 was observed when *E2f1*^{-/-} isolated islet lysates (lane 2) or IgGs (lane 3) were used.

b, Quantification of positive stained islet cells with anti-E2F1, anti-CDK4, anti-pRb and anti-BrdU antibodies.

c, Insulin content of *E2f1*^{+/+} and ^{-/-} isolated islets was measured by RIA and normalized to DNA content (means ± s.e.m., n=5).

Supplementary figure S2. Re-expression of Kir6.2 in *E2f1*^{-/-} isolated islets.

a, Affymetrix results of global gene expression in *E2f1*^{+/+} and ^{-/-} pancreas ; a, genes that are upregulated in *E2f1*^{+/+} pancreas are listed in supplemental table 1; b, genes that are down regulated in *E2f1*^{+/+} pancreas are listed in supplemental table 2. Differential expression of *Kcnj* genes such as *Kcnj11* (arrow) in *E2f1*^{+/+} and ^{-/-} pancreas are represented on the right.

b, Immunofluorescence analysis of KIR6.2 expression (green) in pancreatic islets of *E2f1*^{+/+} and ^{-/-} mice. Hoechst staining of nuclei is in blue.

c, Q-PCR analysis showing expression of *E2f1* and *Kir6.2* mRNA in Min6 cells transfected with a control or *E2f1* siRNA (means ± s.e.m.).

d, Insulin secretion of Min6 cells transfected with a control or *E2f1* siRNA in the presence of 2.8 mM and 20 mM glucose. The experiment was performed in triplicate and results were normalized by DNA content.

e, *Kir6.2* mRNA quantification in *E2f1*^{+/+} and ^{-/-} isolated islets transfected with an empty vector (pCDNA3) or a vector encoding Kir6.2 (pCDNA3-mKir6.2), as described in the methods section.

Supplementary figure S3. Kir6.2 is a bona fide E2F1 target gene.

a, Computational analysis of the regulatory region of the murine *Kir6.2* gene demonstrating the presence of an E2F responsive element (E2F-RE). Comparison of this E2F-RE with the

E2F-REs of classical E2Fs target genes is illustrated. The *Kir6.2* mutated E2F-RE sequence is indicated.

b, Quantification of ChIP experiment by QPCR demonstrating enrichment of E2F1 on the *Kir6.2* promoter.

c, ChIP showing absence of binding of E2F1 to the *ap2/Fabp4* promoters in isolated islets. Immunoprecipitates were analyzed by PCR using specific primers for the *aP2* promoter. As a control, a sample representing 10% of the total chromatin was included in the PCR (Input). IgGs were used as a negative control.

d, *In vitro* binding of the E2F1/DP-1 heterodimer to *Kir6.2* promoter element indicated in . EMSA analysis of the radiolabelled E2F response element of the DHFR promoter (lanes 1-3), *kir6.2* promoter (lanes 4-5), or a mutated *Kir6.2* promoter (lanes 6-7) incubated with Min6 cell extracts transfected with E2F1/DP-1 encoding vectors. Incubation of an anti-E2F1 antibody resulted in a small supershift and clearance of the band (lanes 2, and 5). The cold *Kir6.2* E2F1 binding element competes for binding with the E2F-DHFR element (lane 3).







e, ChIP showing binding of E2F1 to the *Kir6.2* and *Dhfr* promoters in Min6 cells. Immunoprecipitates were analyzed by PCR using specific primers for the E2F-RE present in the *Kir6.2* and *Dhfr* promoters. As a control, a sample representing 10% of the total chromatin was included in the PCR (Input). IgGs were used as a negative control.


Supplementary figure S4. Increased phosphorylation of pRb in islet cells upon glucose treatment.


Micrography representative of phosphorylated pRB staining by IHC of pancreatic sections in mice treated with (n=5) or without glucose (n=5). Higher magnifications of the picture demonstrating positively (black arrowhead) and negatively (red arrowhead) stained cells are represented. Scale bars represent 10 μ m.


Supplementary figure S5. Model of regulation of the CDK4-pRB-E2F1 pathway in the pancreas.





In pancreas the CDK4-pRB-E2F1 pathway exerts both proliferative and metabolic functions, such as the control of both pancreatic growth and insulin secretion, respectively. Under low glucose condition, such as observed during fasting, the *Kir6.2* gene is repressed in β -cell due to the concomitant binding of E2F1, DP-1 and pRb. In response to increased glucose levels, insulin is secreted and acts through an autocrine effect on β -cells, activating the PI3 kinase, which consequently increases CDK4 activity, phosphorylation of pRB and subsequent E2F1 transcriptional activity. In this condition, high glucose concentration will activate transcription of E2F1 target gene, *i.e.* the *Kir6.2* gene.


































Annicotte et al., supplementary figure S4









Full scan of Figure 2b



Full scan of Figure 2d




IP IgG




IP CDK4


Full scan of Figure 3b




Full scan of Figure 3h



Full scan of Figure 4b



Full scan of Figure 4e



Full scan of Figure 5d